Sponsor Directory

Pfizer clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3276

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Breast Cancer
Interventions: ARV-471, Abemaciclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 23
States / cities: Palo Alto, California • San Francisco, California • Tampa, Florida + 11 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 35 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 23
States / cities: Orange, California • Palo Alto, California • San Francisco, California + 20 more

Conditions: Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Advanced or Metastatic Solid Tumors, HGG, LGG, Low Grade Glioma, High Grade Glioma, Differentiated Thyroid Cancer, NSCLC (Non-small Cell Lung Cancer)
Interventions: PF-07799544, PF-07799933; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 44
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Rogers, Arkansas + 22 more

Conditions: Keloid
Interventions: Ritlecitinib; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Transthyretin Amyloidosis, Heart Failure, Heart Failure, Diastolic, Amyloidosis
Interventions: 99mTc-pyrophosphate Scintigraphy; Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 65 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1)
Interventions: PF-07799933, binimetinib, cetuximab, midazolam, fluorouracil, leucovorin, oxaliplatin; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 31
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more

Conditions: Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma
Interventions: Elranatamab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease
Interventions: Voxelotor; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Obesity, Overweight or Obesity
Interventions: MET097, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Anaheim, California • Hollywood, Florida

Conditions: Severe Alopecia Areata
Interventions: Ritlecitinib higher dose, Ritlecitinib lower dose, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 31
States / cities: Irvine, California • Santa Ana, California • Aurora, Colorado + 22 more

Conditions: Migraine
Interventions: Rimegepant, Various, No intervention; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years to 49 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Dermatomyositis, Polymyositis
Interventions: Dazukibart; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 4
States / cities: Glendale, Arizona • Frisco, Texas • Houston, Texas + 1 more

About this Pfizer sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Pfizer is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pfizer trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Pfizer clinical trials

Filter and sort this sponsor

Live official records

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Elranatamab in R/R Multiple Myeloma

Assessing Physical Function in Sickle Cell Patients Taking Voxelotor

A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

About this Pfizer sponsor directory page